New York, Feb 10, 2026, 3:13 PM EST — Regular session
- Thermo Fisher shares slipped roughly 0.8% in afternoon trading, lagging behind other life-science tools stocks.
- The company priced a $3.8 billion senior notes offering in four parts, linked to its upcoming Clario acquisition.
- As the company moves further into 2026, investors are keeping a close eye on financing costs and the pace of the deal.
Shares of Thermo Fisher Scientific Inc slipped roughly 0.8% to $542.62 Tuesday afternoon, moving within a range of $540.99 to $549.82. The stock dropped $4.14 compared to its previous closing price.
On Monday, the company priced $3.8 billion in U.S. dollar-denominated senior notes—corporate bonds that take priority over equity in a liquidation—across four maturities with coupons ranging from 4.215% to 5.546%. Thermo Fisher said it will use the net proceeds to fund the cash portion of its pending acquisition of Clario Holdings.
This matters now since the debt pricing essentially assigns a new cost tag to part of the Clario deal. With rates still driving the market, investors zero in on what fresh borrowing means for leverage and interest expenses, even if the stock barely shifts.
A free writing prospectus tied to the offering was filed Monday, according to a company posting.
Thermo Fisher fell behind a few of its close rivals during the day. Danaher climbed about 1.3%, while Agilent Technologies also rose roughly 1.3% in afternoon trading.
Thermo Fisher’s Clario acquisition has grabbed attention since late January, when the company revealed the deal might reach $9.4 billion and boost adjusted profit per share by 20 to 25 cents by mid-2026. Yet, it also predicted 2026 adjusted profit would fall short of Wall Street’s estimates, citing headwinds from cuts and freezes in U.S. academic research funding. CEO Marc Casper told analysts the guidance factored in “similar conditions” and “customer caution” in that segment, which might ease later this year. Reuters
That said, the situation has its risks. Should credit markets tighten or the Clario deal drag on, Thermo Fisher might have to hold new debt longer than intended or shift its financing strategy, all while demand from academic and government labs continues to fluctuate.
Next on the agenda is execution: Thermo Fisher plans to close the bond offering around Feb. 12. Traders will be closely monitoring the settlement and any new details on the cash financing tied to Clario.
